Glenmark launches Remogliflozin combo in India; GeneCentric Therapeutics buys Select ImmunoGenomics
→ India’s Glenmark in April launched domestically a new SGLT2 inhibitor called Remogliflozin — marking the first-ever launch of the diabetes drug, which was partly developed by GSK $GSK. SGLT2 inhibitors, such as Forxiga, Invokana and Jardiance, work by preventing the kidneys from reabsorbing glucose back into the blood. Remogliflozin will now also be sold in combination with the decades-old metformin in India, Glenmark said on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
